Deutsche Bank

Trust & Securities Services
Paseo de la Castellana, 42-3º
28046 Madrid
Tel. 91 782 8545
Fax: 91 782 8508

Madrid, 11.11.2005

Adjunto le enviamos información de *Investor News of Bayer AG.*

Atentamente,

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Bayer HealthCare: Majority holding in anti-infectives research acquired by Santo Holding AG

Jobs in Wuppertal to remain / closing expected in 1st quarter of 2006

Leverkusen / November 3, 2005 – Bayer HealthCare (BHC) plans to spin off the anti-infectives research unit of its Pharmaceuticals Division into a new company in which the Santo Holding (Deutschland) AG, Stuttgart, Germany, will own a majority holding. Bayer HealthCare will retain a minority holding. The transaction is expected to be completed in the first quarter of 2006.

"The signing of this agreement marks a successful conclusion to the announced spin-off of our anti-infectives research. In addition, we have managed to preserve valuable jobs and thus strengthen the status of Wuppertal as a location for research. I am certain that these highly qualified employees will enjoy a productive environment in the new company," said Dr. Wolfgang Plischke, Head of BHC's Pharmaceuticals Division.

The new company will be headquartered in Bayer HealthCare's Pharmaceutical and Chemical Park in Wuppertal and will be headed by Professor Helga Rübsamen-Waigmann, currently head of BHC's anti-infectives research. Around 25 members of staff will continue to search for new active substances for the treatment of viral and bacterial diseases as employees of this new company in the future. The research fields in question are human cytomegalovirus (HCMV), hepatitis C, HIV, herpes and gram-positive bacteria. The new company will take over various development products and research projects as well as patent rights and licenses from Bayer's Pharmaceuticals Division.

BHC will place both its powerful technology platform and its expertise in production development at the new company's disposal in the context of time-limited service agreements.

"The agreement with Bayer HealthCare serves not only to safeguard the future of a team of professional research scientists but is also a clear commitment to investment in jobs and research in Germany. In addition, our newly established company will have both the technological expertise and the substances it needs to be successful in the search for the innovative drug products needed to treat severe infections," said Dr. Thomas Strüngmann on behalf of Santo Holding AG which is owned by Dr. Andreas and Dr. Thomas Strüngmann and their families.

In late 2004, Bayer HealthCare decided to concentrate on the core therapeutic areas of cancer and cardiovascular risk management including diabetes. The company's late-stage development products include the innovative anticancer substance sorafenib, which has been submitted for regulatory approval in the treatment of renal cell carcinoma in the United States and Europe, and the novel antithrombosis substance BAY 59-7939, which is scheduled to reach Phase III of clinical development shortly.

Leverkusen, November 3, 2005

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ute Krippendorf (+49-214-30-33021)
Ilia Kürten (+49-214-30-35426)
Judith Nestmann (+49-214-30-66836)

Forward-looking statements

Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Fall Financial News Conference of Bayer AG

Bayer boosts third-quarter earnings: operating result doubled

- Third-quarter sales up 19.1 percent to EUR 6,531 million
- Strong gains by all subgroups
- Group net income up from EUR 52 million to EUR 493 million
- Guidance raised again: full-year underlying EBIT expected to increase by about 50 percent

Leverkusen / November 9, 2005 – The Bayer Group boosted earnings again in the third quarter, doubling its operating result: EBIT before special items moved ahead by 101.5 percent to EUR 691 million (2004: EUR 343 million). All three subgroups registered pleasing gains in sales and earnings, significantly improving their cash flow performance. "One thing I can say straight away is that 2005 has been a very good year for Bayer," said Management Board Chairman Werner Wenning at the Fall Financial News Conference in Leverkusen, again raising the guidance for the full year. Bayer now expects full-year underlying EBIT to increase by about 50 percent. In August, the company had predicted that 2005 earnings would be 40 percent above the prior-year figure of EUR 2,117 million. Bayer confirmed its target of generating more than EUR 26 billion in sales in 2005.

Group sales in the third quarter rose 19.1 percent to EUR 6,531 million (2004: EUR 5,485 million). The main reasons for the increase were the acquisition of the Roche OTC activities, business with Lanxess – which now counts as external sales – and, in particular, a 7 percent rise in selling prices. Adjusted for currency and portfolio effects, sales advanced by 8.1 percent. Underlying EBIT more than doubled due to substantial improvements in all subgroups, the largest earnings contributions coming from HealthCare and MaterialScience. Bayer Group earnings before interest, taxes,

depreciation and amortization (EBITDA) before special items climbed by 41.3 percent to EUR 1,164 million (2004: EUR 824 million).

Third-quarter earnings were boosted by net special gains of EUR 179 million, compared to net special charges of EUR 77 million for the same period in 2004. The previously announced changes to Bayer's pension plans in the United States and Germany resulted in a non-cash one-time gain of EUR 280 million in the third quarter. The principal special charges for the period were EUR 33 million for the reorganization of the polyurethanes business, EUR 27 million in write-downs on buildings, EUR 25 million in litigation-related expenses and EUR 13 million in integration costs for the consumer health business acquired from Roche.

EBIT after special items advanced to EUR 870 million (2004: EUR 266 million) in the third quarter, while EBITDA rose by 83.4 percent to EUR 1,370 million (2004: EUR 747 million). Group net income rose even more significantly, improving from EUR 52 million to EUR 493 million. "The third quarter was exceptionally strong, bringing us very close to meeting our profitability targets," said Wenning. Gross cash flow advanced by 46.7 percent to EUR 920 million (2004: EUR 627 million), mainly due to the strong growth in EBIT. Net cash flow climbed by EUR 913 million to EUR 1,438 million.

Gains in all three subgroups

All subgroups contributed to the gratifying overall performance in the third quarter. The strongest growth driver was Bayer HealthCare, which lifted sales by 21.0 percent to EUR 2,373 million (2004: EUR 1,961 million), mainly because of the acquisition of the Roche consumer health business. Adjusted for currency and portfolio changes, sales advanced by 6.5 percent. The Pharmaceuticals Division registered considerable organic growth once again, which more than offset the decline in sales resulting from the patent expiration for Bayer's Cipro® antibiotic in the United States. Levitra® and Trasylol® performed particularly well, while sales of the genetically engineered hemophilia drug Kogenate® improved by 31.7 percent, making it Bayer's best-selling HealthCare product in the third quarter. The HealthCare subgroup's EBIT before special items rose by 12.3 percent to EUR 355 million (2004: EUR 316 million), due in part to the earnings contributions from the alliance with Schering-Plough in the United States.

Wenning said he was also encouraged by the trend at Bayer CropScience. Sales of this subgroup rose by 4.2 percent in the third quarter to EUR 1,171 million (2004: EUR 1,124 million). Currency- and portfolio-adjusted sales remained steady year on year. Less widespread pest infestation in cotton, particularly in the Asia-Pacific region, diminished sales of the Insecticides business unit by nearly 4 percent. While revenues of the Fungicides business unit held steady year on year, sales of Herbicides advanced by just under 10 percent. Business with non-agricultural products expanded even faster, with a 16 percent sales increase, and the BioScience Business Group lifted sales by more than 9 percent. CropScience posted a very dynamic earnings performance in the third quarter, which normally is rather weak for seasonal reasons: Underlying EBIT was back in the black at EUR 17 million following a EUR 108 million loss in the third quarter of 2004. This improvement was due to the absence of goodwill amortization, the success of Bayer's efficiency programs and increased sales of high-margin products.

As in the second quarter, Bayer MaterialScience again saw strong growth. Sales of this subgroup moved ahead by 18.4 percent to EUR 2,639 million (2004: EUR 2,228 million). Currency- and portfolio-adjusted sales rose by 13.4 percent. By contrast to the previous year, BMS succeeded in implementing substantial price increases in the market in light of strong demand and the continuing high cost of raw materials, Wenning explained. Underlying EBIT climbed by 150.7 percent to EUR 366 million (2004: EUR 146 million).

Strong growth in all regions

Sales advanced in all regions in the third quarter – particularly in Europe, where business expanded by 22.1 percent due to the Roche OTC acquisition and a strong performance by MaterialScience. Disregarding the portfolio effects, sales in Germany were up by about 11 percent. Bayer also achieved a very good performance in North America, where all three subgroups contributed to an overall sales increase of about 20 percent. Significantly higher sales were also recorded in Asia/Pacific and Latin America/Africa/Middle East, where sales moved ahead by 14.9 and 14.1 percent, respectively.

Group net income for the first nine months jumps to more than EUR 1.5 billion

The Bayer Chairman was also very satisfied with his company's performance in the first nine months as a whole. Sales for this period grew by 18.2 percent to

20,288 million (2004: EUR 17,167 million), while underlying EBIT rose by 56.2 percent to EUR 2,685 million (2004: EUR 1,719 million). After special items, EBIT climbed by 71.2 percent to EUR 2,620 million (2004: EUR 1,530 million). Net income for the first nine months rose by 151.4 percent to EUR 1,551 million (2004: EUR 617 million).

Positive outlook for the future

The Bayer CEO was optimistic about business trends in the future. "We expect the global economy to go on expanding despite the high price of oil," he explained. In the United States, Bayer anticipates further strong growth, and in Asia the economy appears to be back on a path of rapid growth following a slight dip. In Europe, said Wenning, growth is likely to be more restrained, while in Latin America the company assumes the current upward trend will continue. Bayer anticipates a considerable year-on-year increase in underlying EBIT in the fourth quarter.

Successful alignment toward innovation and growth

"The third-quarter figures show that the strategic realignment of the Bayer Group has sustainably improved our earning power," Wenning said in conclusion. "Our extensive cost-containment and efficiency-improvement measures have paid off." He said that in the third quarter the company had made good progress not only operationally, but also strategically.

With respect to innovation, Wenning reported on encouraging progress with the company's pharmaceutical pipeline. He expects the first half of 2006 to see the U.S. launch of Nexavar® to treat advanced kidney cancer. Phase II and III clinical studies are also currently under way in several other forms of cancer. Together with Johnson & Johnson, Bayer is driving the development of its oral antithrombosis drug, the Factor Xa inhibitor, for which it plans to launch phase III clinical trials in the coming weeks. The Pharmaceuticals Division also has 11 other projects in phase I and 16 more in preclinical development.

Bayer CropScience has already achieved sales of EUR 642 million in the first nine months of 2005 with 16 active ingredients brought to market since the year 2000. Including 10 other new active ingredients it intends to launch from next year onward, the company anticipates total sales potential from its CropScience pipeline of up to EUR 2 billion by 2011. Bayer MaterialScience already generates about 20 percent of its total sales with new products and applications introduced over the past five years.

Group-wide innovation initiative launched

Wenning emphasized that Bayer will spend nearly EUR 2 billion for research and development in 2005. "This is by far the highest budget of all German companies in the chemical and pharmaceutical sector," he said. Furthermore, the company has launched a Group-wide innovation initiative entitled 'Triple-i' – which stands for "inspiration, ideas and innovation." This long-term initiative is designed to encourage Bayer's employees to put forward creative ideas and suggestions that can be utilized for the company's benefit through a special innovation process put in place for this purpose. Emphasis will be placed on examining ideas and possibilities in areas beyond the current scope of Bayer's subgroups or at the interfaces between them.

" 'Triple-i' is intended to promote a culture of innovation at Bayer. In this context we will invest an additional amount of up to EUR 50 million in new research projects next year alone," Wenning announced. First to receive funding as part of this initiative will be a project aimed at manufacturing pharmaceutical active ingredients from plants. "I am convinced that this novel biotechnological approach has the potential to transform the industrial production of pharmaceuticals in the future," explained the Bayer CEO. He said this underscores Bayer's mission to be an inventor company that grows primarily through innovation.

Leverkusen, November 9, 2005

Bayer AG, Investor Relations contacts:
Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)

Bayer

Investor News

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investigator Presents Update on Phase III Sorafenib Trial in Patients with Advanced Kidney Cancer

Leverkusen / November 3, 2005 – Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported that Dr. Bernard Escudier provided an update on the Sorafenib Phase III trial in patients with advanced renal cell carcinoma (RCC), or kidney cancer during the thirteenth European Cancer Conference (ECCO). Dr. Escudier is the Head of Immunotherapy and Innovative Therapy Unit at the Gustave-Roussy Institute, Paris and co-principal investigator of the study along with Ronald Bukowski, M.D., Director of the Experimental Therapeutics Program of The Cleveland Clinic Taussig Cancer Center, Cleveland, OH.

Dr. Escudier reported, based on an interim analysis, that there was an estimated 39 percent improvement in survival for patients receiving Sorafenib versus those receiving placebo ($p=0.018$, hazard ratio 0.72). According to Dr. Escudier, "These data build on the previously announced finding that disease progression was significantly delayed in advanced kidney cancer patients who received Sorafenib. As a clinician who regularly sees individuals suffering from this disease, I am encouraged by this growing body of data and what they may mean for patients and their families."

This interim analysis was conducted while the study was ongoing and soon after the Bayer and Onyx decision to allow patients receiving placebo to "cross over" to treatment with Sorafenib based on ethical considerations. The analysis was based on the 220 survival events (patient deaths) that had occurred by May 31, 2005. The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance ($p< 0.0005$), these early results suggest a favorable survival trend for patients who received Sorafenib.

Phase III Summary

In June 2005, Dr. Escudier presented data from the same study, which demonstrated that Sorafenib significantly prolonged progression-free survival. As independently reviewed, progression-free survival was doubled to a median value of 24 weeks in patients who received Sorafenib as compared to 12 weeks for patients receiving placebo ($p < 0.000001$). In addition, 74 percent of Sorafenib patients had tumor shrinkage as compared to 20 percent of placebo patients.

Based on the statistical and clinical significance of the progression-free survival data, Bayer and Onyx filed a New Drug Application (NDA) in July 2005 requesting approval in advanced renal cell cancer by the U.S. Food and Drug Administration (FDA). Subsequently, the FDA granted the Sorafenib filing priority review status, which means the agency will review the application with a goal of taking action within six months of receipt of the NDA. Additionally in September 2005, a Marketing Authorization Application (MAA) was submitted to the European Medicines Agency (EMEA) to market Sorafenib in Europe.

In the Phase III trial, the rate of significant adverse events (grade 4) was comparable for patients receiving Sorafenib or placebo. Grade 3 adverse events were modestly elevated in the Sorafenib-treated group (31 percent) as compared to placebo patients (22 percent). Drug-related adverse events (all grades) were consistent with those observed in previous clinical trials and included: rash, diarrhea, hand foot syndrome, hair loss, itching, nausea, hypertension, and fatigue.

Phase III Trial Design

More than 900 patients with advanced kidney cancer participated in the international Phase III study. Patients were randomized one-to-one to receive either 400 mg Sorafenib or placebo twice a day. The endpoints of the study include: overall survival, progression-free survival, best response, quality of life (patient-related outcomes), and safety. In April 2005, the study was modified to allow patients who were receiving placebo to "cross over" to drug treatment based on the magnitude of the progression-free survival benefit for Sorafenib-treated patients.

About Sorafenib

Sorafenib (sorafenib tosylate) Tablets, a novel investigational agent, is the first oral multi-kinase inhibitor that targets kinases in both the tumor cell and its vasculature. In preclinical models, Sorafenib blocked kinases known to be involved in proliferation (tumor growth) and angiogenesis (tumor blood supply) - two important cancer growth

activities. These kinases included RAF kinase, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT-3, and RET.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Sorafenib with Bayer Pharmaceuticals Corporation. For more information about Onyx's pipeline and activities, visit the company's web site at: www.onyx-pharm.com.

About Bayer Pharmaceuticals Corporation
Bayer Pharmaceuticals Corporation (www.bayerpharma.com) is part of the worldwide operations of Bayer HealthCare AG, a subgroup of Bayer AG.

Bayer HealthCare, with sales of approximately 8.5 billion Euro in 2004, is one of the world's leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004.

Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Leverkusen, November 3, 2005

Bayer AG, Investor Relations contacts:
Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beumink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ute Krippendorf (+49-214-30-33021)
Ilia Kürten (+49-214-30-35426)
Judith Nestmann (+49-214-30-66836)

Bayer

Q3 2005 Analyst and Investor Briefing

November 9, 2005

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

- **Sales** increased by 19.1% to €6,531m; Volume +1%, price +7%, currency +2%, portfolio +9%.
- **Reported EBIT** grew by €604m to €870m (Q3'04: €266m).
- **Net Special Items** of €179m include:
  HealthCare: Total: €72m: -€13m Roche OTC integration, -€6m Baycol litigation, -€5m PPA litigation; -€27m write-downs on buildings, €122m pension adjustment
  CropScience: Total €53m: €54m pension adjustment
  MaterialScience: Total €40m: -€33m Polyurethanes reorganization; €73m pension adjustment
  Reconciliation: Total €14m: -€14m litigation; €31m pension adjustment
  See also **page 3** of this document for more information regarding pension adjustment.
- **Underlying EBIT** more than doubled to €691m (Q3'04: €343m), which was mainly attributable to higher prices and efficiency improvements.
- **Reported EBITDA** at €1,370m up 83.4% (Q3'04: €747m)
- **Underlying EBITDA** at €1,164m up 41.3% (Q3'04: €824m); Margin at 18%
- **Non-operating result** down by 13.0% to -€182m (Q3'04: -€161m).
- **Net income** (including discontinued operations) improved by €441m to €493m (Q3'04: 52m); EPS accordingly at €0.68 (Q3'04: €0.07).
- **Gross cash flow (cont.)** up 46.7% to €920m (Q3'04: €627m). Cash-in from reduction of **Working Capital (cont.)** €518m. **Net cash flow** (cont.) at €1,438m (Q3'04: €525m). **CapEx** up by 19.7% to €346m. **Operating free cash flow (cont.)** at €1,092 million (Q3'04: €236m).
- **Net debt** down by €897m to €5,978m when compared to June 30, 2005. **Pension liabilities** reduced by €261m to €7,063m, when compared to June 30, 2005 due to adjustment of pension schemes.

	Q3 2004						Q3 2005					
€ million	Sales	EBIT rep.	Special Items	EBIT Clean	EBITDA rep.	EBITDA clean	Sales	EBIT rep.	Special Items	EBIT clean	EBITDA rep.	EBITDA clean
HealthCare	**1,961**	**276**	**(40)**	**316**	**382**	**422**	**2,373**	**427**	**72**	**355**	**589**	**490**
PH/BP	916	96	(28)	124	136	164	1,029	188	30	158	256	214
CC	347	56	(12)	68	74	86	590	74	(2)	76	106	108
DC/DS	503	66	0	66	109	109	542	104	37	67	161	109
AH	195	58	0	58	63	63	212	61	7	54	66	59
CropScience	**1,124**	**(96)**	**12**	**(108)**	**81**	**69**	**1,171**	**70**	**53**	**17**	**227**	**174**
CP	956	(85)	0	(85)	54	54	979	53	44	9	175	131
ES/BS	168	(11)	12	(23)	27	15	192	17	9	8	52	43
MaterialSc.	**2,228**	**119**	**(27)**	**146**	**262**	**289**	**2,639**	**406**	**40**	**366**	**542**	**502**
Materials	839	76	0	76	131	131	1,030	192	27	165	247	220
Systems	1,389	43	(27)	70	131	158	1,609	214	13	201	295	282
Reconc.	**172**	**(33)**	**(22)**	**(11)**	**22**	**44**	**348**	**(33)**	**14**	**(47)**	**12**	**(2)**
Group	**5,485**	**266**	**(77)**	**343**	**747**	**824**	**6,531**	**870**	**179**	**691**	**1,370**	**1,164**

Outlook

The strategic realignment has sustainably enhanced the Bayer Group's operational efficacy and earning power. The extensive action we have taken to contain costs and enhance efficiency has paid off.

We believe the world economy will go on expanding despite high oil prices. The United States should continue to see robust growth. In Asia, too, the economy appears to be back on a path of rapid growth following a slight dip. In Europe, however, we continue to anticipate a more subdued economic environment. In Latin America, the present upward trend should be maintained.

Against the background of the strong third quarter, we are again raising our forecast for the full year. We now expect to improve underlying EBIT by about 50 percent – compared to our previous guidance of 40 percent – from the €2,117 million recorded for last year, and we confirm our target of generating more than €26 billion in sales. Accordingly, we anticipate a significant year-on-year improvement in underlying EBIT in the fourth quarter.

We expect to take net special charges for the full year of between €100 million and €150 million. This figure does not include any additional litigation-related expense, particularly in connection with antitrust proceedings, which currently is not quantifiable (see Stockholders' Letter, Legal Risks, page 20).

We plan total capital expenditures of approximately €1.2 billion in 2005 to safeguard the long term growth of the enterprise. This is equivalent to about 70 percent of projected depreciation and amortization.

We estimate our total research and development expenditures for 2005 at about €1.9 billion, more than 80 percent of which will be spent on the search for new active substances and applications in HealthCare and CropScience.

The aim of our efforts in the coming years will be to match the margins of the best competitors in all of our businesses and to grow at least as fast as our markets. Our performance so far in 2005 shows we are on the right track.

HealthCare

Pharma/Biologicals sales up by 12.3% (Pharma +6.2%; BP +33.8%) to €1,029m driven by continuous strong performance in Europe and the US. Trasylol (€63m; +31.3%) and Levitra (€67m; +48.9%) sales profited from successful promotion efforts in the US. Avelox (€64m; 0%) seasonally weak. Adalat flat (€165m; +1.2%). Aspirin Cardio up 17.9% (€46m). Kogenate (€187m; +31.7%) showed continuing good performance.

Underlying EBIT up 27.4% to €158m due primarily to the growth in business and the earnings contributions from the Schering-Plough alliance.

Consumer Care sales up by 70.0% to €590m (Q3'04 €347m) due to inclusion of Roche OTC business (€258m). Aleve (€51m; -12.1%) still could not fully recover from safety discussions regarding NSAIDs. OTC Aspirin sales dropped by 3.4% to €113m.

Underlying EBIT up by 11.8% to €76m (Q3'04; €68m). Margin burdened by higher D&A, increased marketing spend and one-offs related to the Roche OTC integration.

Diabetes Care/Diagnostics sales up 7.8% to €542m. Diabetes Care grew by 3.9% mainly due to performance in Europe. Diagnostics (€354m; +9.9%) showed favourable growth in US and Europe.

Underlying EBIT flat at €67m (+1.5%).

Animal Health sales increased by 8.7% to €212m, which was mainly due to the good performance of the Advantage product family.

Underlying EBIT came in below last year's level (€54m, -6.9%), which contained €8m in income from a real-estate sale.

CropScience

Crop Protection sales were up 2.4% to €979m. Sales of the **Insecticides** dropped by 3.7% to €289m, which was mainly attributable to a lower pest affection of cotton in Asia. **Fungicides** sales recovered, (€222m; -0.4%), due to the compensation of late effects from the drought in Latin America by higher sales in North America. Favourable sales of Atlantis contributed to a 9.5% sales increase to €335m in the **Herbicides** division. **Seed Treatment** (€133m; +4.7%) profited from the good level of Imidacloprid based applications.
Underlying EBIT in Crop Protection improved by €94m and came in at €9m (Q3'04: -€85m), mainly due to new products and cost savings.

Environmental Science/ BioScience up by 14.3% to €192m. Environmental Science (€145m; +16.0%) profited from the professional segment in North America and Middle East. Increasing sales of FiberMax (cotton) and vegetable seeds originated the sales increase of BioScience by 9.3% to €47m.
Underlying EBIT significantly improved by €31m to €8m (Q3'04: -€23m), which was attributable to the professional segment.

MaterialScience

Materials improved by 22.8% to €1,030m, driven by Polycarbonates (€668m; +29.5%). Price increases in Europe and Asia were mainly attributable.
Underlying EBIT more than doubled to €165m (Q3'04: €76m) mainly due to margin improvement resulting from price increases.

Systems segment sales were up 15.8% to €1,609m, mainly due to Polyurethanes (€1,153m; +12.9%) and Inorganic Basic Chemicals (€96m; +84.6%), both profiting from price increases.
MDI (+29.0%) still on good track, but with slightly decreasing demand in Q3. TDI down yoy by 1.4%. Polyether sales (+5.8%) improved by price increases.

Underlying EBIT significantly up by 187.1% to €201m, resulting mainly from price increases.

Gains from commodity hedges amounted to €13m. Raw material costs remained steady at the previous year's high level.

Summary of one-time pre-tax income due to reduction of pension liabilities in the US (including minor adjustments in Germany):

See also Stockholders' Letter, page 32f

	€ million
HealthCare	122
Pharmaceuticals, Biological Products	47
Consumer Care	15
Diabetes Care, Diagnostics	52
Animal Health	8
CropScience	54
Crop Protection	46
Environmental Science, BioScience	8
MaterialScience	73
Materials	27
Systems	46
Reconciliation	31
Group	280

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group/down management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20F).The company assumes no liability whatsoever to up/downdate these forward-looking statements or to conform them to future events or developments.